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Objectives: To examine microparticles (MPs) from
patients with SLE and healthy controls (HCs) by
determining the cellular origin of the MPs, quantifying
attached fragments of complement component 3 (C3)
and assessing the ability of MPs to bind to circulating
phagocytes and erythrocytes. These features may be
relevant for clearance of MPs in SLE pathogenesis.
Methods: Attached C3 fragments (C3b, iC3b, C3d),
membrane integrity and cell surface markers of MPs
from 18 patients with SLE and 11 HCs were measured
by adding specific antibodies, 7-aminoactinomycin D
(7AAD) and annexin V. MPs from all subjects were
labelled with carboxyfluorescein diacetate succinimidyl
ester and allowed to bind to autologous phagocytes
and erythrocytes in the presence of autologous serum,
and the binding to individual cell populations was
assessed by flow cytometry.
Results: The proportion of MPs bearing C3 fragments
was higher in patients with SLE than in HCs
(p=0.026), but the amount of opsonising C3b/iC3b
molecules was lower (p=0.004). The C3b/iC3b level
correlated with the concentration of circulating C3
(rs=0.53, p=0.036). Phagocytes and erythrocytes
from patients and HCs bound autologous MPs, and
granulocytes from patients bound 13% more MPs
than those from HCs (p=0.043). The presence of
erythrocytes inhibited the MP binding to granulocytes
by approximately 50%.
Conclusions: Our demonstration of altered
composition of C3 fragments on MPs from patients
with SLE, including decreased numbers of opsonising
C3 fragments, and competitive binding of MPs to
circulating phagocytes and erythrocytes corroborates
the hypothesis of defective clearance of apoptotic
material in SLE, and indicates that differences in both
MP opsonisation and binding of MPs to cells are
important in the pathogenesis of SLE.
INTRODUCTION
Microparticles (MPs) are hypothesised as
central in the pathogenesis of SLE, but the
mechanisms involved are unclear. MPs are
small membrane-bound vesicles (0.1–1 µm)
released from activated or apoptotic cells
(ACs).1 They carry, among other, nuclear
antigens triggering the production of various
antinuclear antibodies, a hallmark of SLE.
SLE is a systemic autoimmune disease char-
acterised by activation of the innate immune
system and activation of T and B lympho-
cytes, leading to production of autoanti-
bodies, immune complex (IC) deposits and
complement-mediated tissue damage.2 This
results in clinical manifestations from various
tissues, of which malar rash, non-erosive arth-
ritis and nephritis are among the most
common.3 The disease can range from mild
to severe with varying degrees of organ
damage and is associated with an overall
increased mortality.4
MPs have surface similarities with both ACs
and ICs because the MP surface contains
both phosphatidylserine, other cell surface
markers and antigen–antibody complexes.5
Accordingly, because SLE is associated with
deﬁcient clearance of AC material6–8 and
ICs,9 clearance of MPs is likely to be
impaired in SLE. Clearance of ACs is nor-
mally a non-inﬂammatory process; ACs are
rapidly phagocytised following recognition
via receptors for opsonins, phosphatidylser-
ine or β2-glycoprotein I, exposed on the cell
membrane.7 10 11 ICs are cleared by binding
to erythrocytes via complement receptor type
1 (CR1) that binds C3b, C4b and, with lesser
afﬁnity, iC3b on the IC.12 The ICs are subse-
quently transported to the ﬁxed mono-
nuclear phagocytic system in liver, spleen or
bone marrow.6 9 12–15 Based on this, and pre-
vious ﬁndings of neutrophil MP binding to
erythrocytes, we found it reasonable to
suggest that MPs might be cleared in the
same manners.16 Deﬁciencies in these clear-
ance mechanisms are likely to be impaired
in patients with SLE. Several hypotheses
about AC clearance defects exist. One per-
tains to defects in the receptor-mediated rec-
ognition by phagocytes.7 17 Another focuses
on defects in macrophage phagocytosis.8
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Third, diminished clearance of ACs in SLE is linked to
deﬁciencies in complement components or complement
receptors. For example, one third of patients with SLE
have antibodies against complement, and deﬁciencies of
components of the classical pathway are strongly asso-
ciated with SLE,6 especially C1q deﬁciency.18 Clearing of
ICs is also compromised in patients with SLE, who
express fewer CR1 molecules per erythrocyte than
healthy controls (HCs). Deﬁcient MP clearance might
lead to accumulation of MPs with disrupted membrane
integrity and exposure of antigenic cell material to the
immune system, resulting in a proinﬂammatory
response.7
The qualitative properties of MPs in patients with SLE
are sparsely investigated. It has been demonstrated that
in vitro generated MPs carry double-stranded DNA
(dsDNA) on their surface, and that antibodies from SLE
plasma bind to such MPs. In addition, the surface of
MPs from patients with SLE contains large amounts of
IgG, which correlate with the individual levels of circulat-
ing anti-dsDNA antibodies.5 19 20 This study aimed to
increase the knowledge about mechanisms for clearance
of MPs including their binding to circulating blood cells,
and to determine differences between patients with SLE
and HCs in this respect.
MATERIALS AND METHODS
Patients with SLE and HCs
The patients with SLE were included either as they were
hospitalised with active disease or from our outpatient
rheumatology clinic, and they fulﬁlled internationally
accepted classiﬁcation criteria.21 22 We aimed to include
both patients with disease-active and disease-inactive
SLE, to be able to compare these two groups. Patients
who had a malignant disease, were pregnant or received
cytostatics or high-dose prednisolone (>25 mg/day) were
excluded. We used the scoring index SLE Disease
Activity Index (SLEDAI) 2K 30 days for estimation of
disease activity,23 and we deﬁned active disease as
SLEDAI score ≥5. The HCs examined were blood
donors at the Blood Bank at Copenhagen University
Hospital Rigshospitalet. The study was approved by the
Regional Scientiﬁc Ethics Committee (Protocol no.
H-1-2013-046).
Eighteen patients with SLE, of which 8 had active
disease (SLEDAI ≥5) and 11 HCs, were included in the
study. The patient group consisted of 83% women, com-
pared with 82% in the HC group, and the age was
median (range) 36 (22–69) and 34 (24–54) years,
respectively.
Purification of MPs
We collected 9 mL of blood in a K3EDTA tube
(Vacuette, Greiner Bio-One GmbH) by venous puncture.
The blood was centrifuged at 1800×g for 10 min at 37°C
for cell removal. The supernatant was moved to a Falcon
tube and centrifuged at 3000×g for 10 min at 37°C for
removal of most of the platelets. The remaining platelet
poor plasma was ﬁltered through a 1.2 µm syringe ﬁlter
(Minisart, Sartorius) and divided into aliquots of 460 µL
in Eppendorf tubes. Forty microlitres of Roswell Park
Memorial Institute medium 1640 (RPMI) was added to
each tube. After centrifugation at 19 000×g for 30 min at
21°C, 475 µL supernatant was removed, leaving 25 µL in
the tube. Then 225 µL RPMI, ﬁltered through a 0.1 µm
ﬁlter (Minisart), was added, and the MPs were resus-
pended in a total volume of 250 µL. After a second cen-
trifugation at 19 000×g for 30 min at 21°C, 225 µL was
removed, leaving 25 µL in the tube. Seventy-ﬁve microli-
tres of the ﬁltered RPMI was added, and the MPs were
resuspended in a total volume of 100 µL per aliquot. We
stored the puriﬁed MPs in an incubator at 37°C for 20–
24 hours until analysis or incubation with blood cells.
Analysis of MPs
For determination of the cellular origin of MPs, two
50 µL aliquots of MPs were added to 40 µL of ﬁltered
RPMI and incubated with (1) 5 µL allophycocyanin
(APC) conjugated anti-CD3 (T cells), 10 µL phycoeryth-
rin (PE)-conjugated anti-CD61 (platelets), 5 µL ﬂuores-
cein isothiocyanate (FITC)-conjugated anti-CD146
(endothelial cells); and (2) 3 µL peridinin chlorophyll
protein complex (PerCP)-conjugated anti-CD14 (mono-
cytes), 3 µL anti-CD15-APC (neutrophils), 5 µL
anti-CD19-PE (B cells). For examination of membrane
integrity and exposure of chromatin, one 50 µL aliquot
of MPs were added to 5 µl annexin V and 3 µL 7-
aminoactinomycin D (7AAD), respectively. All antibodies
were from Becton Dickinson (BD), except anti-CD61-PE
(Biolegend). All incubations took place for 30 min,
except for 7AAD, which incubated for 5 min. The
stained MPs were further diluted with 0.1 µm ﬁltered
phosphate-buffered saline (PBS) solutions: calcium-
containing PBS for the tube with annexin V and citrate-
containing PBS for the remaining tubes.17 For quantiﬁ-
cation, we used BD TruCount beads (BD), according to
the manufacturer’s instructions.
The puriﬁed MPs were evaluated by ﬂow cytometry
(BD FacsCalibur) with all detectors in logarithmic
mode. CellQuest software (BD) was used for acquisition,
and we applied Flow Jo software V.7.6.5 (Tree Star) for
analysis. MPs were deﬁned as particles with a diameter
of 0.1–1 µm, and this range in forward scatter was deter-
mined by the aid of Fluoresbrite (Polysciences) size
beads of 0.1 and 1 µm (ﬁgure 1). Unstained samples
were used as controls.
Analysis of C3 fragments on the surface of MPs was
done by means of antibodies against speciﬁc C3 frag-
ments: MPs incubated with FITC-conjugated polyclonal
rabbit anti-C3d antibodies (Dako) for 30 min for assess-
ment of all surface-bound C3 fragments.24 Unstained
samples were used as negative controls. Incubation with
monoclonal antibodies (mAb) recognising C3b and
iC3b (clone f1-23) or iC3b alone (clone f1-7) for
30 min, followed by staining with a PE-conjugated
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secondary antibody (Dako) for 15 min, was used for
quantiﬁcation of these C3 fragments.24 An irrelevant
in-house generated non-reacting antibody in culture
supernatant was used together with the PE-conjugated
secondary antibody as negative control. All samples were
analysed by ﬂow cytometry.
Binding of MPs to blood cells
MPs from 18 patients with SLE and 10 HCs were loaded
with the ﬂuorescent substrate 5 (and
6-)-carboxyﬂuorescein diacetate succinimidyl ester
(CFSE) and incubated with autologous cells: leucocytes,
puriﬁed from 100 µL whole blood subjected to erythro-
lysis with Easy Lyse (Dako; a 4.5% solution), or 100 µL
washed whole blood, or 1 µL diluted (1:100) whole
blood cells. Autologous serum (30% v/v) was present,
and all sera were frozen within 60 min after collection.
After incubation for 1, 5, 15, 30 and 60 min, respectively,
10 µL of the solution was transferred to 1 mL PBS on
ice. The binding of MPs to granulocytes, monocytes and
erythrocytes was measured by ﬂow cytometry as the
CFSE median ﬂuorescence intensity (MFI) of each cell
population.
Within morphological gates based on forward and
side light scatter characteristics, and by staining with
anti-CD45−PerCP, anti-CD15−APC and anti-CD14−PE
(all from BD), granulocytes were identiﬁed as CD45+
and CD15+ cells; monocytes were identiﬁed as CD45+
and CD14+ cells; and erythrocytes were identiﬁed as
CD45−, CD14− and CD15− cells.
Statistical analysis
Differences between HCs, patients with disease-inactive
SLE and patients with disease-active SLE were per-
formed using the Kruskal-Wallis test, and the
Mann-Whitney U test was used when patients with SLE
and HCs were compared. Correlations were determined
by Spearman’s correlation coefﬁcient (rs). The ability of
MPs to bind to cells was assessed by a linear mixed
model for longitudinal measurements, where the loga-
rithm of the CFSE MFI was used as dependent variable,
and the inﬂuence of incubation time and group was
explored; binding was regarded signiﬁcant if the inﬂu-
ence of incubation time was statistically different from
the zero value. The inhibition of binding exhibited by
erythrocytes was calculated as the percentage of binding
Figure 1 Gating of microparticles (MPs). (A) Flouresbrite 0.1 µm beads added to PBS were analysed by flow cytometry to set a
0.1 µm lower limit. (B) Flouresbrite 1.0 µm beads added to PBS were analysed by flow cytometry to set an upper 1.0 µm limit.
(A and B) The final gate for MP analysis is shown. (C and D) Example of gating of stained MPs, including the gate used for
analysis, where panel C shows the ungated forward/sidescatter (FSC/SSC) with the MP gate, panel D shows the unstained
negative control and panel E shows MPs stained with anti-CD61 PE.
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relative to binding without erythrocytes, and was shown
as mean values with 95% CIs. If the interval did not
overlap 100%, the inhibition was considered statistically
signiﬁcant. Statistical analyses were done by means of
SAS Software v. 7.1 (SAS Institute), and ﬁgures were
created in GraphPad Prism (GraphPad Software).
RESULTS
Clinical characteristics of patients with SLE
The patients’ median (range) SLEDAI score was 4
(0–18). Five of the patients with active disease (n=8) had
biopsy-veriﬁed lupus nephritis, one had vasculitis and
transient proteinuria, one had arthritis and pleurisy and
one had arthritis as the only clinical symptom. One
patient with inactive disease was known to have C1q
deﬁciency.
Surface characteristics of MPs from patients with SLE and HCs
The total number of MPs per millilitre whole blood did
not differ between patients with disease-active SLE,
patients with disease-inactive SLE and HCs, and neither
did the distribution of MPs concerning cell surface
markers and membrane integrity: CD3 (p=0.36), CD14
(p=0.82), CD15 (p=0.38), CD19 (p=0.96), CD61
(p=0.44), CD146 (p=0.41), AnxV (p=0.71) and 7AAD
(p=0.98) (ﬁgure 2, see online supplementary table for
exact ﬁgures). As expected, platelet-derived CD61+ MPs
were the most frequent MP type in patients with SLE
and HCs.
The percentage (range) of MPs bearing C3 fragments,
as measured by anti-C3d, was higher in patients with
SLE than in HCs (69.3% (52.1, 94.5) vs 65.0% (50.2,
74.6); p=0.026). In addition, the distribution of C3 frag-
ments differed between patients with SLE and HCs; the
median (range) MFI arising from binding of mAb f1-23,
recognising both C3b and iC3b, to the surface of MPs
from patients with SLE was lower than the correspond-
ing MFI of MPs from HCs (202 (54, 1034) vs 477 (278,
1452); p=0.0044). The C3b+iC3b level correlated with
the level of circulating C3 in the patients measured by
routine methods (rs=0.53, p=0.036) (ﬁgure 3).
Binding of MPs to phagocytes and erythrocytes
Signiﬁcant binding of MPs to granulocytes (p<0.0001),
monocytes (p<0.0001) and erythrocytes (p<0.0001) was
Figure 2 Number of microparticles (MPs) and distribution of MP surface markers in patients with SLE and HCs. Three aliquots
of MPs were incubated with (1) anti-CD3, anti-CD61 and anti-CD146; (2) anti-CD14, anti-CD15 and anti-CD19; and (3) 7AAD
and annexin V, respectively. All incubations took place for 30 min, except for 7AAD, which incubated for 5 min. During
subsequent flow cytometric analysis, MPs were defined as particles with a diameter of 0.1–1 µm, determined by size beads
(Fluoresbrite). For calculation of numbers of MPs per millilitre full blood, BD TruCount beads were added. (A) The concentration
of MPs per millilitre whole blood, (B) the number of MPs binding 7AAD or annexin V, and (C and D) the number of MPs positive
for different surface markers are shown for patients with disease-active (triangles) and patients with disease-inactive (squares)
SLE and for HCs (circles). Bars and error bars represent median and range.
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observed (ﬁgures 4 and 5). There were no statistically
signiﬁcant differences between patients with
disease-active SLE, patients with disease-inactive SLE and
HCs regarding binding of MPs to granulocytes (p=0.11),
monocytes (p=0.84) or erythrocytes (p=0.73). However,
when comparing the whole population of patients with
SLE with HCs, a 13% higher binding of MPs to granulo-
cytes was found in the patient group (p=0.043).
Ability of erythrocytes to inhibit binding of MPs to
phagocytes
The presence of erythrocytes strongly inhibited binding
of MPs to granulocytes and monocytes (ﬁgure 6). The
inhibition of MP binding to granulocytes was statistically
signiﬁcant in patients with SLE and HCs at all time
points, as was the binding to monocytes during the ﬁrst
30 min of incubation. No differences were observed
between HCs, patients with disease-active or patients
with disease-inactive SLE in this respect (ﬁgure 6).
DISCUSSION
The main aim of this study was to investigate C3
fragments on MPs from patients with SLE and the
ability of MPs to bind to circulating phagocytes and
erythrocytes.
Few other studies have investigated the binding of
complement to MPs. Here, we show that patients with
SLE had a higher proportion of MPs with surface-bound
C3 fragments than did HCs. In line with this, Mobarrez
et al25 recently found fourfold to tenfold increased levels
of platelet and endothelial cell-derived MPs expressing
C4d in patients with SLE compared with HCs. Further,
Østergaard et al11 demonstrated increased amounts of
several complement proteins, including C3, on MPs
from patients with SLE. We also found that MPs from
patients with SLE carried diminished amounts of the
opsonising C3b and iC3b fragments. The total amount
of C3 in SLE serum was decreased, presumably as a
result of increased complement C3 activation and con-
sumption.6 Taken together, these ﬁndings indicate that
the reduced amounts of complement C3 available in
patients with SLE are distributed on a relatively larger
proportion of MPs, presumably due to more antibodies
on the surface of SLE MPs, ultimately resulting in dimin-
ished opsonisation of these MPs. This might be one
explanation for the diminished phagocytosis of autoanti-
genic MPs described in SLE.7
Contributing to our ﬁnding of diminished comple-
ment C3b and iC3b fragments on MPs from patients
with SLE may be the presence of C3b-blocking anti-
bodies, as demonstrated by Kenyon et al.26 Reduction of
opsonising signals on MPs from patients with SLE is
further supported by the ﬁnding that patients with SLE
have fewer annexin V-binding MPs, and thereby fewer
MPs expressing phosphatidylserine on the surface, than
do HCs.17 25 The diminished opsonisation of MPs in
patients with SLE is likely to compromise the appropri-
ate clearance of MPs by phagocytosis and via circulating
erythrocytes, which would explain an increased tissue
deposition of MPs, similar to that seen for ICs.27 28
The binding of MPs to granulocytes from patients with
SLE was slightly increased. This might be explained by
enhanced opsoninisation, especially with immunoglobu-
lins, of MPs from patients with SLE, compared with MPs
from HCs.5 Granulocytes from patients with SLE show
decreased phagocytosis of dead cell material,8 but
according to our ﬁndings, this is not related to dimin-
ished ability to take up MPs.
Here, we show that MPs bind equally well to erythro-
cytes from patients with SLE and HCs, and that this
binding restricts the binding of MPs to circulating phago-
cytes, in the same manner as previously shown for ICs.29
Binding of MPs to erythrocytes has previously been
Figure 3 C3 fragment deposition on microparticles (MPs) from patients with SLE and healthy controls (HCs). (A) Purified MPs
from patients with SLE and HCs were incubated with FITC-conjugated, polyclonal rabbit anti-C3d (recognising all C3 fragments)
for 30 min and analysed by flow cytometry. Unstained MPs were used as negative controls to distinguish between C3
fragment-positive and negative MPs. The percentages of MPs bearing C3 fragments are shown as median (range). (B) Aliquots
of purified MPs from HCs and patients with SLE were incubated for 30 min with monoclonal antibodies recognising C3b and iC3b
(clone f1–23) and iC3b alone (clone f1–7), respectively. After staining with PE-conjugated secondary antibody, the samples were
analysed by flow cytometry. A non-reacting control for the primary antibody was used to define C3 fragment-positive MPs, the
fluorescence intensity (FI) of which is shown as median (range). Data from one experiment are missing due to total absence of
events during flow cytometry. (A and B) MPs were defined as all particles with a diameter of 0.1–1 µm by the aid of size beads
(Fluoresbrite). (C) The relationship between the circulating level of C3 and the median C3b+iC3b fragment-derived FI is shown
for patients with SLE.
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Figure 4 Binding of microparticles (MPs) to granulocytes, monocytes and erythrocytes. (A) Isolated leucocytes or (B) whole
blood cells diluted (1:100) were incubated with autologous CFSE-labelled MPs for 5 min in the presence of 33% v/v autologous
serum. (C and D) The gating strategy for granulocytes and monocytes included gating for CD45+ cells and (E and F) positivity
for CD15 or CD14, respectively. (B and G) Erythrocytes were gated as cells negative for CD45, CD14 and CD15. (H–J) The
background fluorescence intensity (FI) after no addition of MPs (red line) and FI after binding of MPs (blue line) are shown. Data
are representative of experiments involving 10 HCs and 18 patients with SLE. CFSE, carboxyfluorescein diacetate succinimidyl
ester; FSC, forward scatter.
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demonstrated by Gasser and Schifferli,16 who found
that neutrophil-derived MPs bound to erythrocytes in
the presence of complement and that addition of
anti-CR1 (3D9) completely abrogated this binding.
However, the ability of erythrocytes to act as a buffer
restricting MP binding to phagocytes is novel.
We speculate that this buffering effect might also
include restriction of MP presentation to antigen-
presenting cells, thereby representing a mechanism to
protect the immune system against autoantigens
present on MPs.
Regarding MP binding to phagocytes, other research
groups have shown that MPs generated in vitro from T
cells and endothelial cells bound to monocytes.30–32 Our
study adds to this by reporting for the ﬁrst time on the
binding of in vivo generated MPs to circulating phago-
cytes, and the potential differences in this binding
between patients with SLE and HCs.
Platelet-derived MPs were the most abundant MP
type in both HCs and patients with SLE, and this is
consistent with earlier studies,17 25 though the percent-
age is not as high as what others have found (see
online supplementary table). A lower percentage of
platelet-derived MPs might be explained by the rapid
centrifugation after sampling (30 min maximum),
which diminishes MP release from platelets during
storage. We found no differences between groups
regarding levels of total MPs, or subfractions of
annexin V-binding MPs; 7AAD-binding MPs; or platelet-
derived, endothelial cell-derived or leucocyte-derived
MPs. Other research groups have found varying differ-
ences in MP numbers and phenotype distribution—
regarding cell of origin and membrane integrity—
between patients with SLE and HCs, but in general,
these studies demonstrate considerable variation in
their results.17 19 25 33–37 It is possible that our study
Figure 5 Binding of microparticles (MPs) to phagocytes and erythrocytes in the presence of autologous serum. Preparations of
(A and B) purified leucocytes, where the erythrocytes had been removed by lysis, and (C) full blood diluted 1:100 in RPMI from
HCs (circles), patients with disease-active (triangles) or patients with disease-inactive (squares) SLE were incubated with
carboxyfluorescein diacetate succinimidyl ester-labelled MPs for 60 min in the presence of 33% (v/v) autologous serum. The
binding of MPs to (A) granulocytes, (B) monocytes and (C) erythrocytes is shown as the mean (95% CI) of the median
fluorescence intensity (MFI) after subtraction of the background fluorescence observed when no MPs were added. One
experiment involving a healthy donor has been excluded due to lack of binding to all cell types.
Figure 6 Erythrocyte-mediated inhibition of microparticle (MP) binding to phagocytes. Preparations of washed whole blood cells
and purified leucocytes, from equivalent amounts of whole blood, collected from healthy controls (circles), patients with
disease-active (triangles) and patients with disease-inactive (squares) SLE were incubated with carboxyfluorescein diacetate
succinimidyl ester-labelled MPs for 60 min in the presence of 33% (v/v) autologous serum. The binding of MPs to (A) granulocytes
and (B) monocytes contained in the preparations of washed whole blood cells is shown as percentage of the corresponding binding
in the preparations of purified leucocytes (=100%, indicated by dotted line). Symbols and error bars represent mean and 95% CI.
One experiment involving a healthy donor has been excluded due to lack of binding to all cell types.
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contributes to such variation by using fresh samples, as
opposed to many other studies using frozen samples.
Also varying use of ﬁltering might play a role. Our
ﬁnding of similar concentrations of total MPs in SLE
and HCs may reﬂect that the supposedly compromised
clearance of MPs in SLE38 is balanced by an increased
tissue deposition.
This study contributes to the growing knowledge
about mechanisms for clearing of MPs in SLE. Our ﬁnd-
ings indicate that the previously demonstrated dimin-
ished phagocytosis of MPs in patients with SLE39 is not
due to diminished binding of MPs to phagocytes.
However, our ﬁnding of reduced amounts of C3b and
iC3b on the surface of MPs may lead to less efﬁcient
opsonisation and phagocytosis of MPs. Our demonstra-
tion of MP binding to erythrocytes supports the theory
that MPs are also cleared by erythrocyte-mediated trans-
portation to the liver, spleen or bone marrow, in parallel
to the mechanism shown for ICs.6 16 40 41 Moreover, our
ﬁnding that erythrocytes restrict the binding of MPs to
granulocytes and monocytes indicates that erythrocytes
buffer opsonised MPs, preventing their inappropriate
activation of circulating phagocytes, as also shown for
opsonised ICs.42 However, unlike previous ﬁndings for
ICs,29 we did not ﬁnd that erythrocytes from our SLE
patients were less able to bind to MPs.
A limitation of this study is that we did not measure
the amount of CR1 on the erythrocytes as our ﬁnding of
the erythrocytes showing equal buffering capacity could
be caused by equal numbers of CR1 on erythrocytes in
the two groups. Another limitation is the lack of measur-
ing the effect of adding anti-CR1 during the incubation
—this would have increased our knowledge about
mechanisms of MP binding to cells.
Future studies should include analysis of the mechan-
isms of MP binding to cells, especially concerning the
role of the receptors involved. Studies are also warranted
investigating the functional aspects of the binding of
MPs to cells shown here, including differences between
patients with SLE and HCs.
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